Progress toward a Respiratory Syncytial Virus Vaccine

Clinical and Vaccine Immunology

Volumn 23, Issue 3, 2016, Pages 186-188

  Neuzil, Kathleen M ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNIZATION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; VACCINATION; VACCINE PRODUCTION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS TRANSMISSION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY;

ANTIBODIES, VIRAL; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL LOAD;

EID: 84962561816     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00037-16     Document Type: Review

References (13)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
2. American Academy of Pediatrics Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. 2014. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134: 415-420. http://dx.doi.org/10.1542/peds.2014-1665.
3. Acosta PL, Caballero MT, Polack FP. 2016. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol 23:189-195. http://dx.doi.org/10.1128/CVI.00609-15.
4. Vissers M, Ahout IML, de Jonge MI, Ferwerda G. 2016. Mucosal IgG levels correlate better with respiratory syncytial virus load and inflammation than plasma IgG levels. Clin Vaccine Immunol 23:243-245. http://dx.doi.org/10.1128/CVI.00590-15.
5. PATH. 2016. Respiratory syncytial virus. Vaccine development against a major cause of childhood respiratory illness. http://sites.path.org/vaccinedevelopment/respiratory-syncytial-virus-rsv/. Accessed 19 January 2016.
6. Poletti P, Merler S, Ajelli M, Manfredi P, Munywoki PK, Nokes D, Melegaro A. 2015. Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings. BMC Med 13:49. http://dx.doi.org/10.1186/s12916-015-0283-x.
7. Karron RA, Luongo C, Thumar B, Loehr KM, Englund JA, Collins PL, Buchholz UJ. 2015. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med 7:312ra175. http://dx.doi.org/10.1126/scitranslmed.aac8463.
8. Chu HY, Steinhoff MC, Magaret A, Zaman K, Roy E, Langdon G, Formica MA, Walsh EE, Englund JA. 2014. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis 210:1582-1589. http://dx.doi.org/10.1093/infdis/jiu316.
9. Eick A, Karron R, Shaw J, Thumar B, Reid R, Santosham M, O'Brien KL. 2008. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J 27:207-212. http://dx.doi.org/10.1097/INF.0b013e31815ac585.
10. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. 1981. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 98:708-715. http://dx.doi.org/10.1016/S0022-3476(81)80829-3.
11. Ochola R, Sande C, Fegan G, Scott PD, Medley GF, Cane PA, Nokes DJ. 2009. The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One 4:e8088. http://dx.doi.org/10.1371/journal.pone.0008088.
12. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. 2003. Correlates of immunity to respiratory syncytial virus (RSV) associatedhospitalization: Establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21:3479-3482. http://dx.doi.org/10.1016/S0264-410X(03)00355-4.
13. U.S. National Institutes of Health. 2015. A study to determine the safety and efficacy of the RSV F vaccine to protect infants via maternal immunization. https://www.clinicaltrials.gov/ct2/show/NCT02624947?term-RSV-vaccines-and-pregnant-women&rank-2. Accessed 18 January 2016.